Hey Subhash,
Simple fact. Look at ROC of Anuh pharma which is at 55% and that of Granules is at 20%.
Its like comparing a BMW with a Nano in my opinion.
Granules keeps diluting and killing shareholders because of its inferior roc while ANUH has NEVER diluted or taken debt thanks to its greater operational metrics.
Impossible comparison in my opinion. Almost a joke to compare Granules with Anuh.
When a company doesnt have much debt, ROCE is not so useful ratio to compare. In such case ROE is the correct matrix. Granules and Anuh has comparable ROE figures.
Hey buddy,
Yeah, they spoke that they “may” give a 1:1 bonus in future. I was myself surprised listening to this! But this is a fact. They said it.
Cheers
Neil
Have any of you received the bonus shares issued
Haven’t received the bonus shares yet.
Bonus shares dont come so soon. It will take between 5-10 days more.
Promoter shareholding seems to have gone up to 71.26% from 65%.
Hello everyone,
Q1 earnings are much above guidance of AR.
Major relief that the company has posted a robust 9.61rs EPS for Q1. Very happy with the performance.
Mr.Bipin Shah is a maverick. Lets hope he delivers on the 5 year target!
Cheers all.
Neil
Management Interview From Money Control
Mangalam: What according to you will be the key growth drivers for Anuh Pharma in FY16-FY17?
A: In FY17 we are introducing six more products; two are already under commercial trials. The existing products are also growing at the rate of about 20 percent on topline and 14 percent on bottomline. Moreover on capital expenditure we are already procured a plot of additional two acre connecting to our current facility. We will be putting up additional Rs 20 crore on the plant which will be commissioned on January 1st 2017.
Reema: Talking about your financials your margins are still low. Why is that and is there a scope for you to improve your margins?
A: The margin always depends on whether you are in a regulatory market or you are in a non-regulatory market. The margins are far better in a regulatory market and our focus is more on regulatory market. Our bottom-line for the current year, we expect to grow additional 40 percent over our last year’s bottom-line.
Mangalam: How much growth are you anticipating on the bottom-line for FY16 and FY17 then, for the next two years?
A: That will be at least Rs 30-32 crore. Rs 45 crore will be the profit before tax and you deduct the tax then it will come to around Rs 32 or 33 crore.
Reema: You also spoke about some additional capex of closed to about Rs 20 crore that you are putting in one plant would that be the Tarapur plant and totally what will the capex be?
A: We are going to fund the new capex from our internal accruals and our reserves only. We are sitting on a huge reserves of more than Rs 100 crore. Everything from internal accruals; no banks finance, no IPO- nothing.
Reema: Your cash on the books you said is Rs 100 crore, right?
A: Cash on books is more than Rs 60 crore because rest is invested in may be working finance or to an extent in a new project that is coming up.
Mangalam: What is your market share in India currently?
A: In India, we should be having about 8-9 percent of the Indian bulk drug production. Mangalam: What is the potential or possibility for you to scale that market share upto? A: It should go upto minimum 20 percent in next five years to come.
Reema: Could you also give us a sense about what your geographical breakup is? You have told us that the focus is a lot on regulatory markets?
A: Out of all the products that we manufacture about 45 percent is exports which is exported to 57 different countries. 55 percent is local sales.
Mangalam: In that case could you give us a sense of what the growth rate for both export and domestic market is? A: The normal growth rate is 15 percent but probably with the new products and the existing products that we manufacture we expect to grow at the rate of 20 minimum and 25 maximum percent.
Reema: What would your current capacity utilisation stand at and can you increase it?
A: Our current capacity utilisation is about 70 percent and we proposed to grow it at the rate of 20 percent because we have already inaugurated one new block in the existing plot. With that our capacity will also substantially grow but we definitely feel that we should grow our capacity utilisation by additional 20 percent year over year.
Mangalam: What is the market share that you have in your key products globally and how much can that increase by?
A: Our current market share of Erythromycins that is around 70 percent of the world market. I am talking Erythromycin. On Pyrazinamide which is an Anti-TB product we are at about 60 percent of the world market share. About Steroids we are at about 30 percent.
Disclosure: Invested from lower levels
Strong 2Q results by Anuh Pharma on November 7, 2015.
----Net sales +29% YoY
----EBITDA margins improves 291bps YoY
----PAT up 56% YoY
Disclosure: Invested from lower levels
Latest company PPT
The company launched 2 new products Ambroxol HCL & Moxifloxacin in the first half of current year. Can anyone help with how one should go about knowing the market size of these 2 products and the number of players / competition in these products?
You may look at the thread on - ValuePickr Generics Pharma Template, could be of some help.
Motilal Oswal has initiated coverage on the company. See the publically available report http://www.motilaloswal.com/site/rreports/635931217880013817.pdf
Anuh Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 11, 2016, inter alia, has declared an Interim Dividend of Rs. 2/- per Equity Share of face value of Rs. 5/- each i.e. 40% for the Financial Year 2015-16.
CFO have been consistently lower than the net profits…inventory and trade receivables are not all that high. then what could be the reason for such poor CFO number
French regulators report GMP failings at Anuh Pharma API processing plant
By Gareth MacDonald+ 30-Mar-2016
Last updated on 30-Mar-2016 at 17:29 GMT
Anuh Pharma has breached GMP rules at its API processing facility in Boisar, India say French regulators who visited the site last month.
According to a report published today, ANSM inspectors observed 24 deficiencies from good manufacturing practices (GMP) at the plant, which provides particle processing – micronization - services.
The major deviation was Anuh’s failure to pass details of its suppliers on to customers to which it sold processed active pharmaceutical ingredients (API).
The ANSM team also reported that azithromycin supplied to Europe labelled as being manufactured by Anuh was actually made by a non-compliant Chinese supplier called Hebei Dongfeng Pharmaceutical.
The inspectors also criticised Anuh’s document management practices after discovering several API repacking records and purchasing orders within a “pile of rubble on the other side of a wall.”
They wrote that: “The findings reveal a critical non-compliance of the quality system of the company as a whole. Moreover, due to the severe lack of transparency of the company regarding its manufacturing activities, there is no assurance as regards to the origin of every batch of active substances claimed to have been manufactured by the company at the Boisar site.
“Consequently, it is considered that the identified risks are applicable to all active substances manufactured at the site.”
GMP certificate
The inspectors also suggested that “withdrawal of current valid EU GMP certificate issued by the Agencia Italiana del Farmaco (IT/E/GMP/9/2013)” be considered.
They also said: “The site has been issued a statement of non-compliance and active substances manufactured by the site should not be used for the manufacturing of medicinal products.”
The EDQM has yet to decide whether to withdraw CEPs issued to Anuh.
most worrying part of report is
if they are buying Chinese non-compliant drug and re labeling and selling it is serious blow to image and may require further digging.
this has really come as surprise as anuh was perceived to have ethical management (& share holder friendly) by market.
I have very little competence for pharma stocks, views from experts will be more valuable .
dis : no holding, was looking to add
Anuh Pharma Ltd has informed BSE that in view of the EDQM suspension, the WHO PQ authorities have suspended Pyrazinamide and Sulfadoxine from the WHO list of prequalified API’s until the WHO led inspection.
Looks like all the cockroaches are coming out of the closet!
Read “WHO suspends pre-qualification of Anuh Pharma’s two APIs” from live mint:
[http://www.livemint.com/Companies/cwPZWJyWG3qeHjTJXNP6IL/WHO-suspends-prequalification-of-Anuh-Pharmas-two-APIs.html]
The WHO suspension is the second blow to the company in less than a month.
